# Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea

> **NCT02727933** · — · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 1941 (actual)

## Conditions studied

- Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02727933
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-03
- **Primary completion:** 2020-07-05
- **Final completion:** 2020-07-05
- **Target enrollment:** 1941 (ACTUAL)
- **Last updated:** 2022-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02727933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02727933, "Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02727933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*